⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2024Science

What’s next for psychedelics after MDMA rejection?

Kai Kupferschmidt

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kai Kupferschmidt (2024) studied this question.

synapsesocial.com/papers/68e5c0f4b6db643587558db5 https://doi.org/10.1126/science.ads4470

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Psychedelics field looks ahead after FDA advisers’ rejection2024 · 3 citations
2Lykos cuts workforce, revamps in wake of FDA decision2024
3Psychedelics’ Use as Medicine Hits Significant Roadblock2024
4FDA advisory committee rejects MDMA application for PTSD, but…2024
5FDA publicly releases MDMA rejection letter; MAPS vows to press forward2025

Market approval and the right to health: a human rights perspective on MDMA-assisted therapy2026
Psychedelics, the media portrayal and large-language model evaluations2026
Patient expectations are a feature of treatment strategy rather than a source of bias2024
Chiral altermagnon in MnTeScience · 2026
Pervasive patterns in bird songs resemble those in human speech and song and are independent of vocal learningScience · 2026

More from Science